| Dr Jonathan Michael Kurss, MD | |
|
401 Bicentennial Way, Medical Office Building 1, Suite 210, Santa Rosa, CA 95403-2149 | |
| (707) 393-4081 | |
| Not Available |
| Full Name | Dr Jonathan Michael Kurss |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 12 Years |
| Location | 401 Bicentennial Way, Santa Rosa, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154685121 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | A142087 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Permanente Medical Group Inc | 8921910225 | 7800 |
News Archive
Parkinson's disease affects between 7 and 10 million people worldwide and the number of people diagnosed is soaring due to the ageing population.
Results from a clinical study demonstrates that microwave measurements can be used for a rapid detection of intracranial bleeding in traumatic brain injuries.
Intercept Pharmaceuticals, Inc., today announced positive results from a 59 patient, placebo controlled, double-blind Phase II clinical trial of obeticholic acid given as monotherapy to patients with primary biliary cirrhosis.
New studies by an international team of scientists led by Joslin Diabetes Center have found variations in a gene that help explain why people with type 2 diabetes are at much greater risk for coronary artery disease, the leading cause of death for this group.
AMDL, Inc., developer and marketer of tests for the early detection of cancer and other serious diseases, announced today that it has filed with the U.S. Food & Drug Administration (FDA) for clearance to market its unique, proprietary DR-70 (FDP) ELISA tumor marker test for use as an aid in monitoring patients previously diagnosed with colorectal cancer. AMDL used the guidance provided at the meeting they had with the FDA on January 25, 2007.
› Verified 4 days ago
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
Parkinson's disease affects between 7 and 10 million people worldwide and the number of people diagnosed is soaring due to the ageing population.
Results from a clinical study demonstrates that microwave measurements can be used for a rapid detection of intracranial bleeding in traumatic brain injuries.
Intercept Pharmaceuticals, Inc., today announced positive results from a 59 patient, placebo controlled, double-blind Phase II clinical trial of obeticholic acid given as monotherapy to patients with primary biliary cirrhosis.
New studies by an international team of scientists led by Joslin Diabetes Center have found variations in a gene that help explain why people with type 2 diabetes are at much greater risk for coronary artery disease, the leading cause of death for this group.
AMDL, Inc., developer and marketer of tests for the early detection of cancer and other serious diseases, announced today that it has filed with the U.S. Food & Drug Administration (FDA) for clearance to market its unique, proprietary DR-70 (FDP) ELISA tumor marker test for use as an aid in monitoring patients previously diagnosed with colorectal cancer. AMDL used the guidance provided at the meeting they had with the FDA on January 25, 2007.
› Verified 4 days ago
| Entity Name | Providence Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285890624 PECOS PAC ID: 8921993205 Enrollment ID: O20040216001346 |
News Archive
Parkinson's disease affects between 7 and 10 million people worldwide and the number of people diagnosed is soaring due to the ageing population.
Results from a clinical study demonstrates that microwave measurements can be used for a rapid detection of intracranial bleeding in traumatic brain injuries.
Intercept Pharmaceuticals, Inc., today announced positive results from a 59 patient, placebo controlled, double-blind Phase II clinical trial of obeticholic acid given as monotherapy to patients with primary biliary cirrhosis.
New studies by an international team of scientists led by Joslin Diabetes Center have found variations in a gene that help explain why people with type 2 diabetes are at much greater risk for coronary artery disease, the leading cause of death for this group.
AMDL, Inc., developer and marketer of tests for the early detection of cancer and other serious diseases, announced today that it has filed with the U.S. Food & Drug Administration (FDA) for clearance to market its unique, proprietary DR-70 (FDP) ELISA tumor marker test for use as an aid in monitoring patients previously diagnosed with colorectal cancer. AMDL used the guidance provided at the meeting they had with the FDA on January 25, 2007.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jonathan Michael Kurss, MD 401 Bicentennial Way, Medical Office Building 1, Suite 210, Santa Rosa, CA 95403-2149 Ph: (707) 393-4081 | Dr Jonathan Michael Kurss, MD 401 Bicentennial Way, Medical Office Building 1, Suite 210, Santa Rosa, CA 95403-2149 Ph: (707) 393-4081 |
News Archive
Parkinson's disease affects between 7 and 10 million people worldwide and the number of people diagnosed is soaring due to the ageing population.
Results from a clinical study demonstrates that microwave measurements can be used for a rapid detection of intracranial bleeding in traumatic brain injuries.
Intercept Pharmaceuticals, Inc., today announced positive results from a 59 patient, placebo controlled, double-blind Phase II clinical trial of obeticholic acid given as monotherapy to patients with primary biliary cirrhosis.
New studies by an international team of scientists led by Joslin Diabetes Center have found variations in a gene that help explain why people with type 2 diabetes are at much greater risk for coronary artery disease, the leading cause of death for this group.
AMDL, Inc., developer and marketer of tests for the early detection of cancer and other serious diseases, announced today that it has filed with the U.S. Food & Drug Administration (FDA) for clearance to market its unique, proprietary DR-70 (FDP) ELISA tumor marker test for use as an aid in monitoring patients previously diagnosed with colorectal cancer. AMDL used the guidance provided at the meeting they had with the FDA on January 25, 2007.
› Verified 4 days ago
Dr. Jennifer V Ratcliffe, M.D., PH.D Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1111 Sonoma Ave, Suite 214, Santa Rosa, CA 95405 Phone: 707-575-5831 | |
Dr. Shazah Khawaja, M.D Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 900 Sonoma Ave Ste 18, Santa Rosa, CA 95404 Phone: 707-579-1102 Fax: 707-579-1386 | |
Estrelania S Williams, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 500 Doyle Park Dr Ste 103, Santa Rosa, CA 95405 Phone: 707-579-1102 Fax: 707-579-1386 | |
Louise Huang, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 500 Doyle Park Dr, #103, Santa Rosa, CA 95405 Phone: 707-579-1102 Fax: 707-579-1386 | |
John C. Parker, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 401 Bicentennial Way, Santa Rosa, CA 95403 Phone: 707-571-4000 | |
Sarah Alexis Paul Padua, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 34 Mark West Springs Rd Fl 2, Santa Rosa, CA 95403 Phone: 707-541-7902 Fax: 707-573-5413 |